Potent P2Y12 Inhibitors in Low-Risk Patients: Is There a Medical Need?

Johanne Silvain; Mathieu Kerneis; Gilles Montalescot

doi:10.1016/j.jacc.2015.11.043

Potent P2Y12 Inhibitors in Low-Risk Patients: Is There a Medical Need?

J Am Coll Cardiol. 2016 Feb 16;67(6):614-617. doi: 10.1016/j.jacc.2015.11.043.

Authors

Johanne Silvain¹, Mathieu Kerneis¹, Gilles Montalescot²

Affiliations

¹ Sorbonne Université-Université Paris 06 (UPMC), ACTION Study Group, INSERM UMR_S 1166, ICAN, Institut de Cardiologie, Hôpital Pitié-Salpêtrière (AP-HP), Paris, France.
² Sorbonne Université-Université Paris 06 (UPMC), ACTION Study Group, INSERM UMR_S 1166, ICAN, Institut de Cardiologie, Hôpital Pitié-Salpêtrière (AP-HP), Paris, France. Electronic address: gilles.montalescot@aphp.fr.

PMID: 26868684
DOI: 10.1016/j.jacc.2015.11.043

No abstract available

Keywords: acute coronary syndrome; coronary artery disease; percutaneous coronary intervention; platelet aggregation inhibitors; prasugrel hydrochloride.

Publication types

Editorial
Comment

MeSH terms

Acute Coronary Syndrome / therapy*
Adenosine / analogs & derivatives*
Female
Humans
Male
Percutaneous Coronary Intervention / methods*
Preoperative Care / methods*
Ticlopidine / analogs & derivatives*
Troponin / blood*

Substances

Troponin
Adenosine
Ticlopidine